<DOC>
	<DOC>NCT00125034</DOC>
	<brief_summary>This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor (EGFR)-expressing mCRC.</brief_summary>
	<brief_title>Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Firstline mCRC EGFR positive Bidimensional measurable index lesion Previous exposure to EGFRtargeting therapy Previous oxaliplatinbased therapy Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented &gt; 6 months after end of adjuvant treatment Radiotherapy Surgery Any other investigational drug in the 30 days before randomization Brain metastasis and/or leptomeningeal disease Acute or subacute intestinal occlusion or history of inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>FOLFOX-4</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>First-line mCRC</keyword>
	<keyword>EGFR positive</keyword>
	<keyword>metastatic CRC</keyword>
</DOC>